As traditional VC investment remains selective, firms like Abingworth and Vie Ventures are pioneering fresh approaches—launching billion-dollar trials …
As traditional VC investment remains selective, firms like Abingworth and Vie Ventures are pioneering fresh approaches—launching billion-dollar trials …
Shanghai-based Excalipoint secures rights to two preclinical T-cell engagers from Lepu Biopharma, aiming to fast-track development for solid …
The CGM giant and smart ring innovator join forces to integrate biosensor data and reshape personal health tracking.
Outlook Therapeutics trims staff and recalibrates its regulatory strategy after its wet AMD trial falls short, underscoring the …
Facing partnership setbacks and pipeline pressure, Editas Medicine lays off 65% of its staff and pivots toward its …
With a fresh $153 million in funding, Strand Therapeutics is pushing the boundaries of mRNA technology—this time, in …
Already a subscriber? Log in